Search This Blog

Thursday, January 9, 2020

Amicus Therapeutics sees FY 2019 Galafold revenue as high as $181M

Amicus Therapeutics (NASDAQ:FOLD) announces preliminary 2019 revenue and Galafold (migalastat) commercial updates.
Global revenue for Galafold in Q4 was ~$54M and for FY 2019 was ~$181M, exceeding updated 2019 guidance of $170M to $180M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)